



US006037368A

**United States Patent** [19]

Podos et al.

[11] **Patent Number:** 6,037,368[45] **Date of Patent:** Mar. 14, 2000[54] **8-ISO- PROSTAGLANDINS FOR GLAUCOMA THERAPY**[75] **Inventors:** Steven M. Podos, Tenaflly, N.J.;  
Thomas W. Mittag, Pleasantville, N.Y.;  
Bernard Becker, University City, Mo.[73] **Assignee:** Mount Sinai School of Medicine, New York, N.Y.[21] **Appl. No.:** 09/073,552[22] **Filed:** May 6, 1998**Related U.S. Application Data**

[63] Continuation of application No. 08/853,803, May 9, 1997, abandoned.

[51] **Int. Cl.<sup>7</sup>** ..... A61K 31/215; A61K 31/19[52] **U.S. Cl.** ..... 514/530; 514/573; 514/913[58] **Field of Search** ..... 514/530, 573, 514/913[56] **References Cited****U.S. PATENT DOCUMENTS**4,132,847 1/1979 Kuhla et al. .  
4,599,353 7/1986 Bito .  
5,151,444 9/1992 Ueno et al. .  
5,173,507 12/1992 DeSantis et al. .5,208,256 5/1993 Ueno .  
5,262,437 11/1993 Chan .  
5,462,968 10/1995 Woodward .  
5,476,872 12/1995 Garst et al. .  
5,565,492 10/1996 DeSantis et al. .  
5,578,618 11/1996 Stjernschantz .  
5,631,287 5/1997 Schneider ..... 514/530**FOREIGN PATENT DOCUMENTS**

9411002 5/1994 WIPO .

**OTHER PUBLICATIONS**Podos et al., Mar. 15, 1998, Invest. Ophthalmol. Visual Sci. 39(4):S258, abstract 1178-B57 (title on the Internet several months earlier, believed to be in 1998).  
Wang et al., Mar. 15, 1997, Invest. Ophthalmol. Visual Sci. 38(4):S815, abstract 3795-B396.*Primary Examiner—Zohreh Fay**Attorney, Agent, or Firm—Bakerbotts LLP*[57] **ABSTRACT**The present invention relates to the use of 8-iso prostaglandins and their derivatives for decreasing intraocular pressure, for example in the treatment of glaucoma. It is based, at least in part, on the discovery that 8-iso prostaglandin E<sub>2</sub> effectively decreased intraocular pressure by a trabecular meshwork outflow mechanism.**21 Claims, No Drawings**

1007333-02102